A Phase 3, Multicentre, Randomized, Open-label Study Of Avelumab (msb0010718c) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer
A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to
demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in
prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society